Compugen, Teva Announce Agreement on Treatment for Inflammatory Diseases
Israeli drug firms Compugen and Teva Pharmaceutical reported that they have signed an agreement covering CGEN-54, a Compugen-discovered novel splice variant of MCP1 to treat chronic inflammatory diseases.
The agreement covers both an initial research collaboration and an option to Teva for a worldwide exclusive development and commercialization license, Compugen and Teva said.
According to the agreement, Compugen said it will provide Teva with research quantities of CGEN-54. Teva said it will then conduct further in vivo validation experiments and has received from Compugen an option to enter into an exclusive, worldwide milestone and royalty-bearing license agreement for the development and commercialization of any resulting products.